Careful phase-I trial planning 'saves time and delays'
The latest report from business intelligence firm Cutting Edge Information highlights the importance of planning carefully ahead of the initiation of phase-I trials.
Trial designers can greatly reduce the likelihood of unnecessary delays during phase-I clinical testing by planning ahead, a study has shown.
In its latest report, Cutting Edge Information reveals that the average trial is delayed by 5.3 months.
A typical trial was found to be 20.6 months in duration, despite being planned to take just 15.3 months.
The most susceptible to delays are oncology trials, according to the research, with the average trial of this type planned to take 23.8 months but actually taking over a year longer (36.1 months).
Patient recruitment challenges are often the main cause of these delays, along with problems with the management of multiple clinical trials sites, according to the business intelligence firm.
However, the report suggests that by spending a larger proportion of phase-I trials in the planning stage, biopharmaceutical companies can avoid lengthy delays.
Ryan McGuire, lead research analyst at Cutting Edge Information, also noted: "When delays do occur, companies can implement amendments to the trial design that can broaden the criteria for enrolment and ease the recruitment process.
Related News
-
News CPHI Frankfurt 2022: Innovator Interview – DSM Biomedical
At CPHI Frankfurt we spoke to Anne-Cecile Bayne, Global Science & Innovation Lead Pharma and Medical Nutrition, and Marc Hendriks, Vice President Strategy & Business Development, on their expertise in nitrosamines and business strategy at DSM Biomedica... -
News New WHO health emergency guidelines expect full transparency from Big Pharma
The WHO are proposing a new set of pandemic guidelines to set out how future global health crises should be handled. -
News Magic mushrooms could be used to treat mental health conditions
A compound found in magic mushrooms, psilocybin, could be used to treat mental health conditions and help patients suffering with severe depression, as shown by the results of the largest study of its kind to date. -
News UK-based partnership to launch DETERMINE study into rare cancer research
UK-based CRO Quanticate is set to partner with Cancer Research UK for the launch of the DETERMINE study focused on testing a range of existing and approved drugs and therapies on rare cancers. -
News FDA approves Thermo Fisher blood tests for wheat and sesame allergies
Both tests have been approved by the US regulator for in vitro diagnostic use -
News QIAGEN launches world’s first syndromic test for monkeypox
The test can distinguish between monkeypox and other diseases that cause similar symptoms. -
News Monkeypox Update: Vaccine shortage, sewage surveillance and global testing
As concern over the monkeypox outbreak continues to rise, we take a look at major developments from the first week of August. -
News CPHI Podcast Series: The importance of novel excipients for innovative drug development
The latest episode in the CPHI Podcast Series dives into the world of novel excipients and explores their importance for innovative drug development.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance